🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Leukemia, Myelomonocytic, Chronic

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse NCT06928662Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. NCT06566742Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583Phase 28 sites📍 Birmingham📍 Leeds📍 London Imperial College London · Tests: EBX-102, Placebo Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML NCT05807932Phase 1, Phase 26 sites📍 Aachen📍 Düsseldorf📍 Cologne Heinrich-Heine University, Duesseldorf · Tests: Venetoclax, Amsacrine, Ara-C, Tacrolimus, Mycophenolate Mofetil Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant NCT06543381Phase 12 sites📍 Duarte📍 Cleveland City of Hope Medical Center · Tests: Biospecimen Collection, Olutasidenib IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) NCT06647862Phase 343 sites📍 Hefei📍 Beijing📍 Chongqing ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Tests: IMM01, Azacitidine, Placebo Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia NCT03896269Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Liposome-encapsulated Daunorubicin-Cytarabine Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies NCT06904066Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500 Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS NCT04708054Phase 2, Phase 31 site📍 Houston M.D. Anderson Cancer Center · Tests: Busulfan, Cladribine, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Thiotepa Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML NCT05584761Phase 1, Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: unrelated umbilical cord blood Myeloproliferative Neoplasms (MPNs) Patient Registry NCT02760238n/a1 site📍 Toronto University Health Network, Toronto · Tests: Observational Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome NCT07582172Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776Phase 11 site📍 Palo Alto Stanford University · Tests: Tacrolimus, Early Tacrolimus Taper Strategy Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations NCT07143669n/a26 sites📍 Birmingham📍 Birmingham📍 Scottsdale Blueprint Medicines Corporation · Tests: Screening A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT06859424Phase 213 sites📍 Birmingham📍 Duarte📍 Palo Alto Center for International Blood and Marrow Transplant Resear… · Tests: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT03850574Phase 1, Phase 234 sites📍 Birmingham📍 Duarte📍 Irvine Aptose Biosciences Inc. · Tests: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML NCT05641259Phase 13 sites📍 Nanchang📍 Suzhou📍 Zhengzhou Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: LP-108, Azacitidine Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis NCT06691217Phase 21 site📍 Boston Massachusetts General Hospital · Tests: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo) 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia NCT03128034Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Rad… Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia NCT07071155EARLY Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Momelotinib, Azacitidine A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts NCT05365035Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Venetoclax, Azacitidine Therapeutic RSK1 Targeting in Myeloid Malignancies NCT07379125Phase 11 site📍 St Louis Washington University School of Medicine · Tests: PMD-026 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances NCT05092451Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034Phase 17 sites📍 Stanford📍 Tampa📍 Boston Solu Therapeutics, Inc · Tests: STX-0712 Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia NCT07033598Phase 26 sites📍 Tampa📍 Atlanta📍 Rochester Theradex · Tests: Pacritinib, Hydroxyurea CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia NCT04375631Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement NCT06111612n/a1 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy